ARNA:NSD-Arena Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 99.99

Change

0.00 (0.00)%

Market Cap

USD 6.17B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ARNA Stock Forecast & Price:
Based on the Arena Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Arena Pharmaceuticals Inc is not available over the next 12 months. Arena Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Arena Pharmaceuticals Inc is Slightly Bullish , which is based on 2 positive signals and 1 negative signals. At the last closing, Arena Pharmaceuticals Inc’s stock price was USD 99.99. Arena Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +67.91% over the last year.

About Arena Pharmaceuticals Inc (ARNA:NSD)

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerati ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.43%)

USD76.14B 13.80 10.63
VRTX Vertex Pharmaceuticals Inc

-3.26 (-1.11%)

USD73.02B 23.28 15.15
MRNA Moderna Inc

+0.18 (+0.15%)

USD46.19B 3.66 2.45
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.28 (+0.96%)

USD30.98B 2.87 1.32
RPRX Royalty Pharma Plc

-0.15 (-0.37%)

USD27.19B 39.06 19.32
SGEN Seagen Inc

+1.13 (+0.83%)

USD25.40B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

-9.23 (-4.41%)

USD25.13B N/A -31.40
GMAB Genmab AS

+0.20 (+0.63%)

USD21.66B 41.88 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARNA

Symbol Name Weight Mer Price(Change) Market Cap
LABU Direxion Daily S&P Biotec.. 0.00 % 0.96 %

+0.12 (+1.74%)

USD1.02B
ROGS Hartford Multifactor Glob.. 0.00 % 0.34 %

N/A

USD0.02B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.27 (+0.90%)

USD0.11B
VALX Validea Market Legends ET.. 0.00 % 0.79 %

N/A

USD0.01B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.46 (+0.58%)

USD7.34B
MJ ETFMG Alternative Harvest 0.00 % 0.75 %

-0.07 (-1.50%)

USD0.41B
MJX ETFMG Alternative Harvest.. 0.00 % 0.00 %

N/A

N/A
CBDX:LSE The Medical Cannabis and .. 0.00 % 0.80 %

+0.12 (+2.49%)

USD0.02B
FLWG:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

+1.45 (+0.55%)

USD0.02B
FLWR:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

+0.05 (+1.78%)

USD0.02B
BLUM:XETRA Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

+0.06 (+1.99%)

USD0.02B
CBSX:XETRA The Medical Cannabis and .. 0.00 % 0.80 %

+0.07 (+1.48%)

USD0.02B
BLUM:F Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

N/A

USD0.02B
CBSX:F Hanetf ICAV - Hanetf Alte.. 0.00 % 0.80 %

N/A

USD0.02B
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

N/A

USD0.18B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.59% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.59% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 66.65% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.65% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 292.12% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 292.12% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 27.28% 75% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.28% 75% C 83% B
Risk Return Profile  
Volatility (Standard Deviation) 28.44% 54% F 28% F
Risk Adjusted Return 95.94% 95% A 87% B+
Market Capitalization 6.17B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.40 N/A N/A N/A N/A
Price/Book Ratio 9.16 N/A N/A N/A N/A
Price / Cash Flow Ratio -13.64 N/A N/A N/A N/A
EV/EBITDA 3.52 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -70.30% N/A N/A N/A N/A
Return on Invested Capital -68.19% N/A N/A N/A N/A
Return on Assets -34.53% N/A N/A N/A N/A
Debt to Equity Ratio 5.37% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.79 N/A N/A N/A N/A
Short Percent 11.32% N/A N/A N/A N/A
Beta 0.55 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.